Literature DB >> 7381858

Soft drugs. 2. Soft alkylating compounds as potential antitumor agents.

N Bodor, J J Kaminski.   

Abstract

A class of soft alkylating compounds as potential anticancer agents was developed. The first examples include alpha-halo esters of various carboxylic acids. A new method for quantitative evaluation of the alkylating reactivity was developed, using a competitive alkylation reactivity was developed, using a competitive alkylation reaction, followed by NMR analysis of the reaction mixture. The method is sensitive and reproducible. One of the two selected soft alkylating agents, chloromethyl hexanoate, was found to have anticancer activity.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7381858     DOI： 10.1021/jm00179a018

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.

Authors:  Nicholas Bodor; Peter Buchwald
Journal:  Mol Biotechnol       Date:  2004-02       Impact factor: 2.695

Review 2.  Chemical delivery systems and soft drugs: Retrometabolic approaches of drug design.

Authors:  Yashumati Ratan Bhardwaj; Ashutosh Pareek; Vivek Jain; Dharma Kishore
Journal:  Saudi Pharm J       Date:  2013-05-09       Impact factor: 4.330

3.  Soft drugs based on hydrocortisone: the inactive metabolite approach and its application to steroidal antiinflammatory agents.

Authors:  R J Little; N Bodor; T Loftsson
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

Review 4.  Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs.

Authors:  Chaoyi Deng; Jin Liu; Wensheng Zhang
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

5.  Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats--for safer treatment of gastrointestinal inflammation.

Authors:  N Bodor; T Murakami; W M Wu
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.